Actively Recruiting
A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
Led by Boryung Pharmaceutical Co., Ltd · Updated on 2025-09-12
1052
Participants Needed
2
Research Sites
115 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery
CONDITIONS
Official Title
A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily signed informed consent after study explanation
- Confirmed primary breast cancer by histological diagnosis
- Require neoadjuvant chemotherapy or adjuvant chemotherapy after surgery
- Scheduled to receive non-ethanol formulation docetaxel chemotherapy
- Able to understand and cooperate with study procedures until completion
You will not qualify if you...
- Diagnosed with other primary cancers affecting breast cancer treatment or prognosis
- Diagnosed with secondary breast cancers
- Breast cancer staged as 0/1 (Tis, N0, M0) or Stage IV (any T, any N, M1)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Chung-Ang University Hospital
Seoul, South Korea, 06973
Actively Recruiting
2
Uijeongbu Eulji Medical Center, Eulji University
Uijeongbu-si, South Korea, 11759
Not Yet Recruiting
Research Team
S
Shin-young Oh
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here